Refine
Has Fulltext
- yes (267)
Is part of the Bibliography
- yes (267)
Year of publication
- 2023 (12)
- 2022 (23)
- 2021 (20)
- 2020 (10)
- 2019 (14)
- 2018 (14)
- 2017 (14)
- 2016 (13)
- 2015 (6)
- 2014 (14)
- 2013 (11)
- 2012 (14)
- 2011 (12)
- 2010 (9)
- 2009 (2)
- 2008 (2)
- 2007 (3)
- 2006 (2)
- 2005 (5)
- 2004 (3)
- 2003 (1)
- 1994 (10)
- 1993 (16)
- 1992 (6)
- 1991 (6)
- 1990 (9)
- 1989 (2)
- 1988 (5)
- 1987 (5)
- 1986 (2)
- 1984 (1)
- 1983 (1)
Document Type
- Journal article (221)
- Doctoral Thesis (41)
- Conference Proceeding (3)
- Preprint (2)
Language
- English (267) (remove)
Keywords
- Virologie (33)
- HIV (18)
- Immunologie (16)
- T cells (15)
- measles virus (12)
- SARS-CoV-2 (11)
- Dendritische Zelle (7)
- dendritic cells (7)
- regulatory T cells (7)
- T-Lymphozyt (5)
- immune evasion (5)
- CD28 (4)
- COVID-19 (4)
- Lymphozyt (4)
- Ratte (4)
- T cell (4)
- autoimmunity (4)
- cell staining (4)
- ceramides (4)
- monocytes (4)
- sphingolipids (4)
- sphingomyelinase (4)
- Dendritic cells (3)
- Immunreaktion (3)
- Masernvirus (3)
- Maus (3)
- Medizin (3)
- Parkinson’s disease (3)
- South Africa (3)
- T cell receptor (3)
- Toleranz (3)
- antiretroviral therapy (3)
- ceramide (3)
- evolution (3)
- flow cytometry (3)
- gene expression (3)
- herpesvirus (3)
- immunology (3)
- macrophages (3)
- phosphoantigen (3)
- 3D tissue model (2)
- AIDS (2)
- Antigen CD8 (2)
- Antikörper (2)
- Apoptosis (2)
- BTN3 (2)
- Blimp-1 (2)
- CD1d (2)
- CD4(+) (2)
- CTLA-4 (2)
- Candida albicans (2)
- Dendritic cell (2)
- GFAP (2)
- GM-CSF (2)
- HHV-6 (2)
- HIV-Infektion (2)
- Herpes (2)
- Herpesvirus (2)
- Human papillomavirus (2)
- Immunology (2)
- KDELR2 (2)
- ME/CFS (2)
- Natürliche Killerzelle (2)
- Parkinson (2)
- Prion (2)
- Proteinkinase B (2)
- RNA polymerase II (2)
- Spumaviren (2)
- T cell receptors (2)
- TCR (2)
- TGF-BETA (2)
- TNF-alpha (2)
- Tansania (2)
- Tanzania (2)
- Treg (2)
- VLA-1 (2)
- Viren (2)
- Virology (2)
- Virus (2)
- acid ceramidase inhibitor ceranib-2 (2)
- acid sphingomyelinase (2)
- activation (2)
- alpaca (2)
- antibodies (2)
- antigen presentation (2)
- binding protein (2)
- bone marrow (2)
- butyrophilin (2)
- butyrophilin 3 (2)
- cytokine secretion (2)
- cytokines (2)
- cytotoxic T cells (2)
- dendritic cell (2)
- depression (2)
- domain (2)
- expression (2)
- foamy virus (2)
- foamy viruses (2)
- fusion and fission (2)
- gene regulation (2)
- herpes simplex virus (2)
- human (2)
- identification (2)
- in-vivo (2)
- infection (2)
- inflammation (2)
- latency (2)
- lymph nodes (2)
- measels virus (2)
- measles (2)
- miR-30 (2)
- miRNA processing (2)
- mitochondria (2)
- mouse (2)
- neuroprotection (2)
- neutral sphingomyelinase-2 (2)
- peripheral nervous system (2)
- phylogenetic analysis (2)
- plasma membrane (2)
- rat (2)
- replication (2)
- reverse transcriptase (2)
- sialic acid (2)
- small interfering RNAs (2)
- sphingolipid (2)
- sphingosine kinase inhibitor SKI-II (2)
- sphingosine-1-phosphate (2)
- tolerance (2)
- transcription (2)
- translation (2)
- type I interferon (2)
- viral infection (2)
- viral load (2)
- virology (2)
- virus (2)
- virus reactivation (2)
- γδ T cell (2)
- 1,2-benzisothiazolinone (1)
- 2',7'-dichlorofluorescin (1)
- 3D Ko-kulture (1)
- 3D cell culture (1)
- 3D-Modell (1)
- 5`-UTR (1)
- 60-nucleotide duplication (1)
- ABCG2 (1)
- ACH-2 (1)
- AKT-signaling (1)
- APOBEC3G (1)
- ASM (1)
- ATP-adenosine triphosphate (1)
- ATRA (1)
- Actinomycetes (1)
- Activation (1)
- Adaptive cell transfer (1)
- Aktivierung (1)
- Aktivierung <Physiologie> (1)
- Allotransplantation (1)
- Alpha therapy (1)
- Alzheimer’s disease (1)
- Aminobisphosphonat (1)
- Aminobisphosphonate (1)
- Antibody (1)
- Antibody responses (1)
- Antigen CD4 (1)
- Antigen presentation (1)
- Antigenpräsentation (1)
- Antikörperantworten (1)
- Antisense (1)
- Apoptose (1)
- Aspergillus fumigatus (1)
- Auto-antibodies (1)
- Autoimmune diseases (1)
- Autoimmunity (1)
- Autoimmunität (1)
- Autophagie (1)
- Autophagy (1)
- B cells (1)
- B-Lymphozyt (1)
- B-cell (1)
- B-cells (1)
- B-zells (1)
- BBC3 (1)
- BCG (1)
- BK virus (1)
- BTN (1)
- BTN2 (1)
- BTN2A1 (1)
- BTN3A1 (1)
- Bakterien (1)
- Bauchspeicheldrüsenkrebs (1)
- Biologie (1)
- Biomarkers (1)
- Blutbildendes Gewebe (1)
- Bone marrow transplantantation (1)
- Bowen’s disease, periungual (1)
- Braak (1)
- Brugia Malayi (1)
- Bruton Tyrosine Kinase (1)
- Bryophyta (1)
- C-terminal domain (1)
- CCS (1)
- CD 8 (1)
- CD25+CD4+ regulatory T cells (1)
- CD28 costimulation (1)
- CD28 superagonist (1)
- CD28 superagonists (1)
- CD28-SA (1)
- CD39 (1)
- CD4(+) T-cells (1)
- CD4(+)CD25(+) (1)
- CD4+ T cells (1)
- CD46 (1)
- CD4\(^{+}\) T cells (1)
- CD4\(^{+}\) T helper cells (1)
- CD73 (1)
- CD8+ T cells (1)
- CLEC16A (1)
- CMV (1)
- CNS infection (1)
- COVID‐19 (1)
- COVID‐19 vaccination (1)
- CRAC (1)
- CSF (1)
- Ca2+ (1)
- Calu-3 (1)
- Cancer (1)
- Candida (1)
- Cell migration (1)
- Cell signalling (1)
- Ceramid (1)
- Ceramide (1)
- ChIP-seq (1)
- Children (1)
- Cytomegalie-Virus (1)
- Cytotoxicity (1)
- Cytotoxizität (1)
- D665 (1)
- DAPI staining (1)
- DAT (1)
- DETC (1)
- DNA sequence (1)
- DNA transcription (1)
- DNA traps (1)
- Desaktivierung (1)
- Diabetes mellitus (1)
- Diabetes mellitus Typ 1 (1)
- Diagnostik (1)
- Disease genetics (1)
- Disease severity (1)
- Dolutegravir (1)
- Donor lymphocytes (1)
- EBV (1)
- EVER1 (1)
- EVER2 (1)
- Einfluss (1)
- Enterovirus (1)
- Enzyme-linked immunosorbent assay (1)
- Epidemiology (1)
- Epithelzelle (1)
- Escherichia coli infections (1)
- Evaluation (1)
- Expression (1)
- Extracellular domain (1)
- Factor receptor (1)
- Fanconi Anemia (1)
- Farnesyl Pyrophosphate Synthase (1)
- Farnesylpyrophosphatsynthase (FPPS) (1)
- Fibroblasten (1)
- Flt3L (1)
- Flymphozyt (1)
- Foamy virus (1)
- Frühe Gene (1)
- G glycoprotein (1)
- GBS (1)
- GRP78 (1)
- GagPol fusion protein (1)
- Gen (1)
- German people (1)
- Germany (1)
- Glucocorticoid receptor (1)
- Glucocorticosteroide (1)
- Glukocorticioid (1)
- Glukokortikoid Rezeptor (1)
- Golgi (1)
- Graft versus Tumor (1)
- Graft-versus-leukemia (1)
- Granzyme B (1)
- Grippe (1)
- Guillain-Barré-Syndrom (1)
- HAND (1)
- HCMV (1)
- HHV-6A (1)
- HIV Drug resistance (1)
- HIV South Africa (1)
- HIV diagnosis and management (1)
- HIV infections (1)
- HIV neurocognitive impairment (1)
- HIV-1 (1)
- HIV-1 subtype AG (1)
- HIV-1-infected patients (1)
- HIV-1; subtype C; proviral plasmid; viral replication; resistance assays; Vpu; CD317; CD4 (1)
- HTLV-I (1)
- Hamburg (1)
- Herpesviren (1)
- Herpesviruses (1)
- Homing (1)
- Hsp90 (1)
- Human foamy virus bel-l transactivator; Expression in insect cells (1)
- Hypnales (1)
- ICP27 (1)
- ICP4 (1)
- IE3 (1)
- IFN-gamma (1)
- IL-2 (1)
- IL-3 (1)
- IL1RA (1)
- IL‐10 (1)
- Ibrutinib (1)
- IgG (1)
- Immunesupression (1)
- Immunisierung (1)
- Immunität <Medizin> (1)
- Immunological synapse (1)
- Immunosuppression (1)
- Immunstimulation (1)
- Immunsuppression (1)
- Immunsupression (1)
- Immuntoleranz (1)
- Impfstoff (1)
- Impfung (1)
- IncRNA (1)
- Infectious disease (1)
- Influenza (1)
- Integrase (1)
- Integrase inhibitor (1)
- Integrin (1)
- Interaction (1)
- Interferon (1)
- Interferon <gamma-> (1)
- Interferon gamma (1)
- Interferonantagonism (1)
- Interferonantagonismus (1)
- Isopentenyl pyrophosphate (IPP) (1)
- Isopentenyl-pyrophosphat (IPP) (1)
- Isoprenoid Synthesis (1)
- Isoprenoide (1)
- Isoprenoidsynthese (1)
- JCV (1)
- Jurkat cells (1)
- KRAS (1)
- Karibisches Meer (1)
- Kerinokeratosis papulosa (1)
- Kohlenstoff (1)
- Kongress (1)
- Krebs <Medizin> (1)
- LAD (1)
- LFA-1 (1)
- LIF (1)
- Langerhans cells (1)
- Lentivirus (1)
- Ligand (1)
- MCMV (1)
- MEK/ERK-signaling (1)
- MHC I (1)
- MHC II (1)
- MIR-155 (1)
- MPO (1)
- MRI (1)
- MS (1)
- MV receptor (1)
- MV transcription (1)
- Macrophage (1)
- Major depression (1)
- Major splice donor (1)
- Makrophagen (1)
- Malignancies (1)
- Masern (1)
- Masern-Virus (1)
- Measles virus (1)
- Mechanismus (1)
- Medicine (1)
- Mesocestoides corti (1)
- Mineralocorticoid receptor (1)
- Mineralokortikoid Rezeptor (1)
- Mitochondria (1)
- Molekularpathologie (1)
- Monocytes and macrophages (1)
- Monozytendifferenzierung (1)
- Moose (1)
- Motoneuron (1)
- Multiple Sklerose (1)
- Multiple myeloma (1)
- Multiple sclerosis (1)
- Mycobacterium tuberculosis (1)
- Myelin Basic Protein Promoter (1)
- Myeloid-derived suppressor cells (1)
- Myeloma (1)
- N-CAM (1)
- N-oleoyl serinol (1)
- NFAT (1)
- NFATc1 (1)
- NFKB (1)
- NK cells (1)
- NKT (1)
- NKT Zellen (1)
- NKT cells (1)
- NRF2 (1)
- Nail unit (1)
- Nanoröhre (1)
- Neisseria meningitidis (1)
- Neuritis (1)
- NfL (1)
- Notch1 (1)
- Nucleus (1)
- Ovalbumin (1)
- PAR-CLIP (1)
- PARM (1)
- PCI-32765 (1)
- PCLS (1)
- PKB (1)
- PKB/Akt (1)
- PKCζ, (1)
- PML (1)
- PO (1)
- PVM (1)
- Parkinsonism (1)
- Pathogenese (1)
- Pathway (1)
- Persistenz (1)
- Phage Display (1)
- Placebo (1)
- Pneumoviruses (1)
- Po (1)
- Polyadenylation (1)
- Polyadenylierung (1)
- Polymerase chain reaction (1)
- Polyoma-Virus (1)
- Polyomaviren (1)
- Polyomavirus JC (1)
- Prednisolon (1)
- Primaten (1)
- Priming (1)
- Prion protein (1)
- Prionkrankheit (1)
- Prionprotein (1)
- Prodigy (1)
- Prognose (1)
- Proliferation (1)
- Proteine (1)
- R0 (1)
- RAG1 (1)
- REDD1 (1)
- RNA (1)
- RNA Interferenz (1)
- RNA export (1)
- RNA interference (1)
- RNA structure (1)
- RNS (1)
- RNS-Viren (1)
- RQQ domain (1)
- RSV (1)
- RSV-A ON1 (1)
- RT-qPCR (1)
- Regluation (1)
- Regulation (1)
- Regulation of protease activity (1)
- Regulatorische T Zellen (1)
- Regulatorischer T-Lymphozyt (1)
- Regulatory T cells (1)
- Regulatory-cells (1)
- RelB (1)
- Replikation (1)
- Respiratory tract infection (1)
- Retroviren (1)
- Retroviren-Infektion (1)
- Rheumatoid arthritis (1)
- SARS-CoV-2 brain disorders (1)
- SARS‐CoV‐2 (1)
- SARS‐CoV‐2 infection (1)
- SLAM CDW150 (1)
- STEMI (1)
- STIM1 (1)
- STIM2 (1)
- Salmo trutta fario (1)
- Schwämme (1)
- Seahorse XF (1)
- Sekundärmetabolit (1)
- Sequenzanalyse (1)
- Sialylsäure (1)
- Skint1 (1)
- Sphingosine-1-phosphate (1)
- Sphingosine-1-phosphats (1)
- Subtyp C (1)
- Superagonistic antibody (1)
- Suppression (1)
- Synthese (1)
- Südafrika (1)
- T Cells (1)
- T Lymphozyt (1)
- T Zell Selektion (1)
- T Zellen (1)
- T cell activation (1)
- T cell acute lymphoblastic leukemia (1)
- T cell development (1)
- T cell migration (1)
- T cell selection (1)
- T cell silencing (1)
- T cell suppression (1)
- T helper 1 cells (1)
- T helper cell responses (1)
- T- Zelle (1)
- T-ALL (1)
- T-Zelle (1)
- T-cell (1)
- T-zellen (1)
- TAB08 (1)
- TAMs (1)
- TCF1 (1)
- TCF12 (1)
- TCR signaling cascade (1)
- TCRb (1)
- TGN1412 (1)
- TLR2 (1)
- TLR4 (1)
- TNF (1)
- TRDV2 (1)
- TRGV9 (1)
- Tamoxifen (1)
- Targeted Therapies (1)
- Th1 cells (1)
- Thymozyten (1)
- Thymus (1)
- Tiermodell (1)
- Tierversuch (1)
- Tissue engineering (1)
- Tr1 (1)
- Transcription (1)
- Transgen (1)
- Transgene (1)
- Transgene Tiere (1)
- Transkriptionsfaktor (1)
- Tumor Microenvironment (1)
- Tumor-necrosis-factor (1)
- Tumorwachstum (1)
- Uganda (1)
- Vaccination (1)
- Vaccine (1)
- Vero E6 (1)
- Vg9Vd2 T Zellaktivierung (1)
- Vg9Vd2 T cell (1)
- Vgamma9Vdelta2 (1)
- Vietnam (1)
- Viral infections (1)
- Virus-like particles (1)
- Virus-ähnliche Partikel (1)
- Vγ9Vδ2 (1)
- Vγ9Vδ2 T cell (1)
- WASp (1)
- Waxy papulosis of childhood (1)
- Wiskott-Aldrich syndrome (1)
- Zell Migration (1)
- Zelldifferenzierung (1)
- Zellkonjugation (1)
- Zellrezeptor (1)
- Zentralnervensystem (1)
- Zytokine (1)
- acetylsalicylic acid (1)
- acid ceramidase (1)
- acquisition of host regulators (1)
- actins (1)
- acute Graft versus Host Disease (1)
- acute graft-versus-host disease (1)
- acute heart failure (1)
- acute kidney injury (1)
- adaptive immune response (1)
- adenosine (1)
- adhesion (1)
- admission screening (1)
- adoptive transfer (1)
- adult (1)
- age groups (1)
- aging (1)
- allogeneic stem cell transplantation (1)
- alpha-globin (1)
- alternative splicing (1)
- alveoar echinococcosis (1)
- amplicon sequencing (1)
- anemia (1)
- anergy (1)
- angiogenesis (1)
- animal models (1)
- anthocyanin (1)
- anti-depressant drug (1)
- anti-hiv agents (1)
- anti-myocardial (1)
- anti-protease (1)
- anti-retroviral agents (1)
- antidepressants (1)
- antigen-B (1)
- antigenic recall (1)
- antimicrobial resistance (1)
- antiretrovirals (1)
- antiviral activity (1)
- antiviral treatment (1)
- antivirals (1)
- anti‐SARS‐CoV‐2‐spike IgG (1)
- anxiety (1)
- aorta (1)
- aorta ring (1)
- apoptosis (1)
- arthritis (1)
- aspirin (1)
- astaxanthin (1)
- attachment glycoprotein (1)
- autoantibodies (1)
- autoantibody (1)
- azapeptide nitriles (1)
- azido-ceramides (1)
- azidothymidine (1)
- bacteria (1)
- bacterial pathogens (1)
- bilberry (1)
- binding analysis (1)
- biochemical assays (1)
- bioinformatic (1)
- black currant (1)
- black trout syndrome (1)
- blocking opsonization (1)
- blocking phagocytosis (1)
- brain (1)
- brain bank (1)
- brain pathology (1)
- brain stem (1)
- branch point (1)
- brown trout (1)
- butyrophilin 2A1 (1)
- butyrophilins (1)
- cDC2 subset (1)
- calcium (1)
- calnexin (1)
- cancer microenvironment (1)
- canine distemper virus (1)
- cardiac magnetic resonance imaging (1)
- cardiorespiratory centre (1)
- caveolin-1 (Cav-1) (1)
- cell cycle and cell division (1)
- cell differentiation (1)
- cell line specificity pyridyl indole carboxylates (1)
- cell line-specificity (1)
- cell membrane (1)
- cell membrane model (1)
- cell migration (1)
- cell-cycle dependence (1)
- cells (1)
- cellular receptor (1)
- cellular stress responses (1)
- central-nervous-system (1)
- ceramidase (1)
- cerebrospinal fluid (1)
- channel (1)
- characterization and analytical techniques (1)
- chikungunya virus (1)
- child (1)
- children (1)
- cholera (1)
- cholesteryl ester (1)
- chondrogenesis (1)
- chromatin (1)
- chronic rhinosinusitis (1)
- circulation patterns (1)
- cis-acting sequences (1)
- co-evolution (1)
- co-stimulation, (1)
- coevolution (1)
- cognitive dysfunction (1)
- complement (1)
- complement factor H (1)
- complex (1)
- conversion (1)
- coronavirus (1)
- criteria (1)
- critically ill (1)
- cross-linking (1)
- cryptic peptides (1)
- cytokine release (1)
- cytokine release syndrome (1)
- cytokine responses (1)
- cytoskeleton (1)
- decay (1)
- defective ribosomal products (1)
- degradation (1)
- demyelination (1)
- dengue virus (1)
- diacylglycerol (1)
- diagnostic (1)
- diet (1)
- differential diagnosis (1)
- differentiation (1)
- direct-acting antivirals (1)
- disease severity (1)
- diversity (1)
- dmrt1 (1)
- dna-binding protein (1)
- dogs (1)
- dopamine (1)
- drug adherence (1)
- drug discovery (1)
- drug interactions (1)
- embryo (1)
- encephalitis (1)
- endothelial cell infection (1)
- endothelial cells (1)
- enhance viral transcription (1)
- env leader protein (1)
- enzyme-linked immunoassays (1)
- enzymes (1)
- epicutaneous (1)
- epitope mapping (1)
- epitope specificity (1)
- epstein-barr virus (1)
- exclusion criteria (1)
- excretory-secretory (1)
- factor H (1)
- fibroblasts (1)
- fluorescence-activated cell sorting (1)
- fluoxetine (1)
- foamy retrovirus (1)
- foamyviruses (1)
- fungal infection (1)
- gamma-interferon (1)
- gammadelta T cells (1)
- gene delivery (1)
- gene-expression (1)
- genetic conservation (1)
- genetic interference (1)
- genetic variability (1)
- genetics (1)
- glial damage (1)
- glial fibrillary acidic protein (1)
- glucocorticoid (1)
- glycolipids (1)
- glycoproteins (1)
- glycosphingolipids (1)
- granulosus (1)
- granzyme B (1)
- group B genotype (1)
- group-A (1)
- guidelines (1)
- hACE2 (1)
- healthcare workers (1)
- heart (1)
- heart failure (1)
- helminth infection (1)
- helminths (1)
- hemagglutinin (1)
- hematological disorders (1)
- hepadnaviruses (1)
- heroine (1)
- herpes virus (1)
- highly-active antiretroviral therapy (1)
- histones (1)
- homeostasis (1)
- homing (1)
- host shutoff (1)
- host-pathogen interactions (1)
- human behaviour (1)
- human bocavirus (1)
- human cytomegalovirus (HCMV) (1)
- human immunodeficiency virus (1)
- human peripheral blood (1)
- humans (1)
- hydatid disease (1)
- immediate early genes (1)
- immune activation (1)
- immune cells (1)
- immune control (1)
- immune escape (1)
- immune neuromelanin (1)
- immune response (1)
- immune suppression (1)
- immune therapy (1)
- immuno suppression (1)
- immunoglobulin superfamily (1)
- immunomodulatory (1)
- immunoprecipitation (1)
- immunosuppression (1)
- immunosurveillance (1)
- immunotherapy (1)
- improves survival (1)
- in vitro culture (1)
- in vivo (1)
- indinavir (1)
- inducible deletion (1)
- inducible nitric oxide synthase (1)
- infarction size (1)
- infected mice (1)
- infected-cell protein (1)
- infection control (1)
- infection spread (1)
- infectivity assays (1)
- influenza (1)
- influenza A virus (1)
- influenza virus (1)
- injecting drug users (1)
- innate immune response (1)
- innate lymphoid cells (1)
- interferon (1)
- interferon signaling (1)
- interferon γ (1)
- interleukin 1 receptor antagonist (1)
- interleukins (1)
- kidneys (1)
- large gene lists (1)
- larvae (1)
- lethality rate (1)
- leukemia (1)
- lipids (1)
- liposome (1)
- lithium (1)
- long terminal repeat (1)
- luciferase assay (1)
- lymphocyte activation (1)
- lymphomas (1)
- lyso-phospholipids (1)
- lytic infection (1)
- mTORC1 (1)
- magnetic properties and materials (1)
- major depression (1)
- major histocompatibility complex (1)
- management (1)
- marine sponge (1)
- mechanism (1)
- mediated suppression (1)
- medical (1)
- medical research (1)
- memory B cells (1)
- meningococcal disease (1)
- mesenchymal stem cell (1)
- messenger RNA (1)
- metacestode vesicles (1)
- mevalonate pathway (1)
- miRNA (1)
- miRNA target (1)
- miRNS (1)
- mice (1)
- microRNA (1)
- microbial mutation (1)
- microbiology (1)
- migration (1)
- molecular biology (1)
- molecular characterization (1)
- monocyte (1)
- monocyte differentiation (1)
- moonlighting (1)
- morbilliviruses (1)
- morphine (1)
- mortality (1)
- mothers (1)
- motif discovery (1)
- motifs (1)
- motility (1)
- mouse models (1)
- movement disorders (1)
- mukosale Immunantwort (1)
- multi-drug resistance (1)
- multihit targeting (1)
- multiple myeloma (1)
- multiple sclerosis (1)
- murine cytomegalovirus (MCMV) (1)
- murine model (1)
- mutant mice (1)
- mutation databases (1)
- mycobacteria (1)
- myelin (1)
- myeloid-derived suppressor cell (MDSC) (1)
- myeloid-derived suppressor cells (MDSC) (1)
- myeloid-derived suppressor cells (MDSCs) (1)
- myocardial infarction (1)
- naloxone (1)
- nanobiocomposites (1)
- nanoparticles (1)
- nasal polyps (1)
- necrosis-factor-alpha (1)
- nervous-system (1)
- neurodegeneration (1)
- neurofilament light chain (1)
- neuroinflammation (1)
- neuroinvasion (1)
- neurological symptoms/disorders (1)
- neurovirulence (1)
- neutral sphingomyelinase (1)
- neutral sphingomyelinase 2 (1)
- next generation sequencing (1)
- nine-banded armadillo (1)
- non-canonical translation (1)
- non-nucleoside reverse transcriptase inhibitors (1)
- nucleosides (1)
- oligomers (1)
- opioids (1)
- ortholog (1)
- orthoreovirus (1)
- outpatients (1)
- ovarian cancer (1)
- oxidative phosphorylation (1)
- oxidative stress (1)
- pH-regulated antigen 1 (Pra1) (1)
- pancreatic cancer (1)
- parainfluenza virus (1)
- parasitic diseases (1)
- parasitology (1)
- pathogenesis (1)
- pediatric infections (1)
- pediatrics (1)
- pellet culture (1)
- peptidomimetics (1)
- peripheral tolerance (1)
- persistierende Infektion (1)
- perspectives (1)
- phagocytosis (1)
- phosphoantigens (1)
- phospholipidosis (1)
- piscine orthoreovirus (1)
- placental mammals (1)
- plasminogen (1)
- pneumona virus (1)
- pol messenger-rna (1)
- polarization (1)
- poly(A) site usage (1)
- polyadenylation (1)
- polymicrobial sepsis (1)
- polymorphism (1)
- polyomavirus (1)
- polyomaviruses (1)
- population coverage (1)
- postmortem studies (1)
- pre-messenger RNA (1)
- precision-cut lung slices (1)
- prediction (1)
- prevention (1)
- primary cells (1)
- proliferative darkening syndrome (1)
- promoter-proximal pausing (1)
- protease inhibitors (1)
- protein regulation and expression (1)
- protein sequencing (1)
- proteomic analysis (1)
- protocol (1)
- public health medicine (1)
- purine-rich element (1)
- quality of life (1)
- randomized controlled clinical trial (1)
- randomized controlled-trial (1)
- reactivation (1)
- recognition (1)
- recombinant proteins (1)
- recombination (1)
- regulation (1)
- regulatory T cells (Treg) (1)
- regulatory protein ICP27 (1)
- remdesivir (1)
- resistance (1)
- respiratory syncytial virus (1)
- respiratory tract (1)
- restriction factors (1)
- retroviral infection (1)
- retroviral proteins (1)
- retroviral vectors (1)
- retroviruses (1)
- reverse transcriptase inhibitors (1)
- reverse transcriptase-polymerase chain reaction (1)
- reverse-transcriptase (1)
- reverse-transcriptase inhibitors (1)
- ribonuclease H (1)
- routine clinical-practice (1)
- salicylic acid (1)
- self-reactivity (1)
- sepsis (1)
- sequence (1)
- sequence databases (1)
- seroprevalence (1)
- serum (1)
- sex-determining gene (1)
- shock (1)
- signal transduction (1)
- simian foamy viruses (1)
- sphingomonads (1)
- sphingosine 1-phosphate (1)
- sphingosine kinase (1)
- spleen (1)
- splice regulation (1)
- splicing (1)
- splicing inhibition (1)
- spread (1)
- steady state (1)
- steady-state dendritic cells (1)
- sterol pathway (1)
- strains (1)
- stress (1)
- stroke (1)
- subacute sclerosing-panencephalitis (1)
- subgroup-B (1)
- subviral particle release (1)
- surface transport (1)
- surfactants (1)
- surveillance (1)
- tanzania (1)
- terminal gag domain (1)
- testing strategy (1)
- the microtubule-organizing center (1)
- therapy (1)
- thermal stresses (1)
- thymocyte (1)
- tissue (1)
- tolerogenic dendritic cells (1)
- toll-like receptors (1)
- toxins (1)
- transcription factors (1)
- transcriptional profiling (1)
- transcriptional termination (1)
- transcriptomics (1)
- transcutaneous (1)
- transduction (1)
- transient regulatory T-cell targeting (1)
- transmembrane protein (1)
- tumor (1)
- tumor associated macrophages (1)
- tumour immunology (1)
- type 1 (1)
- type 1 ICP27 (1)
- tyrosine (1)
- ultraviolet radiation (1)
- unwindase (1)
- vaccination and immunization (1)
- vaccinia virus (1)
- vero cells (1)
- vesicles (1)
- viral epidemiology (1)
- viral miRNAs (1)
- viral microRNAs (1)
- viral pathology (1)
- viral replication (1)
- viral shedding (1)
- virale Proteine (1)
- virulence (1)
- virus budding (1)
- virus entry (1)
- virus host interaction (1)
- virus replication (1)
- virus vectors (1)
- virus-induced encephalitis (1)
- viruses (1)
- vitamin-D-receptor (1)
- vivo (1)
- wild-type (1)
- world health organization (1)
- α-synuclein-specific T cells (1)
- γδ T cells (1)
- γδ TCR (1)
Institute
- Institut für Virologie und Immunbiologie (267) (remove)
Sonstige beteiligte Institutionen
- Datenintegrationszentrum Würzburg (DIZ) (1)
- Interdisziplinäre Biomaterial- und Datenbank Würzburg (ibdw) (1)
- Interdisziplinäres Zentrum für Klinische Forschung (ZIKF), Würzburg (1)
- Joslin Diabetes Center, Harvard Medical School (1)
- Roche Diagnostics GmbH Penzberg (1)
- University of Stellenbosch, Division of Medical Virology (1)
EU-Project number / Contract (GA) number
- 721016 (4)
- 101041177 (1)
- 249177 (1)
- 677673 (1)
- 825575 (1)
- 955974 (1)
- CoG 721016–HERPES (1)
- ERC-2016-CoG 721016-HERPES (1)
DNA synthesis and adenosine(S')tetraphosphate(S ')adenosine (Ap.A) levels decrease in cells treated with EDTA. The inhibitory effect of EDTA can be reversed with micro molar amounts of ZnCI2• ZnCh in micromolar concentrations also inhibits Ap.A hydrolase and stimulates amino acid-dependent Ap.A synthesis, suggesting that Zn2+ is modulating intracellular Ap.A pools. Serum addition to GI-arrested cells enhances uptake of Zn, whereas serum depletion leads to a fivefold decrease of the rates of zinc uptake. These results are discussed by regarding Zn2+ as a putative 'second messenger' of mitogenic induction and Ap.A as a possible 'third messenger' and trigger of DNA synthesis.
Herpes simplex virus 1 (HSV-1) is an important human pathogen and a paradigm for virus-induced host shut-off. Here we show that global changes in transcription and RNA processing and their impact on translation can be analysed in a single experimental setting by applying 4sU-tagging of newly transcribed RNA and ribosome profiling to lytic HSV-1 infection. Unexpectedly, we find that HSV-1 triggers the disruption of transcription termination of cellular, but not viral, genes. This results in extensive transcription for tens of thousands of nucleotides beyond poly(A) sites and into downstream genes, leading to novel intergenic splicing between exons of neighbouring cellular genes. As a consequence, hundreds of cellular genes seem to be transcriptionally induced but are not translated. In contrast to previous reports, we show that HSV-1 does not inhibit co-transcriptional splicing. Our approach thus substantially advances our understanding of HSV-1 biology and establishes HSV-1 as a model system for studying transcription termination.
Background
Herpesviruses can infect a wide range of animal species. Herpes simplex virus 1 (HSV-1) is one of the eight herpesviruses that can infect humans and is prevalent worldwide. Herpesviruses have evolved multiple ways to adapt the infected cells to their needs, but knowledge about these transcriptional and post-transcriptional modifications is sparse.
Results
Here, we show that HSV-1 induces the expression of about 1000 antisense transcripts from the human host cell genome. A subset of these is also activated by the closely related varicella zoster virus. Antisense transcripts originate either at gene promoters or within the gene body, and they show different susceptibility to the inhibition of early and immediate early viral gene expression. Overexpression of the major viral transcription factor ICP4 is sufficient to turn on a subset of antisense transcripts. Histone marks around transcription start sites of HSV-1-induced and constitutively transcribed antisense transcripts are highly similar, indicating that the genetic loci are already poised to transcribe these novel RNAs. Furthermore, an antisense transcript overlapping with the BBC3 gene (also known as PUMA) transcriptionally silences this potent inducer of apoptosis in cis.
Conclusions
We show for the first time that a virus induces widespread antisense transcription of the host cell genome. We provide evidence that HSV-1 uses this to downregulate a strong inducer of apoptosis. Our findings open new perspectives on global and specific alterations of host cell transcription by viruses.
Myeloid-derived suppressor cells (MDSCs) represent a major population controlling T cell immune responses. However, little is known about their molecular requirements for homing and T cell interaction to mediate suppression. Here, we investigated the functional role of the homing and collagen IV receptor VLA-1 (α1β1-integrin) on in vitro GM-CSF generated murine MDSCs from wild-type (WT) and CD49a/α1-integrin (Itga1\(^{−/−}\)) gene-deficient mice. Here, we found that effector (Teff) but not naive (Tn) CD4\(^+\) T cells express VLA-1 and monocytes further up-regulated their expression after culture in GM-CSF when they differentiated into the monocytic subset of resting MDSCs (R-MDSCs). Subsequent activation of R-MDSCs by LPS+IFN-γ (A-MDSCs) showed increased in vitro suppressor potential, which was independent of VLA-1. Surprisingly, VLA-1 deficiency did not influence A-MDSC motility or migration on collagen IV in vitro. However, interaction times of Itga1\(^{−/−}\) A-MDSCs with Teff were shorter than with WT A-MDSCs on collagen IV but not on fibronectin substrate in vitro. After injection, A-MDSCs homed to the splenic red pulp where they co-localized with Teff and showed immediate suppression already after 6 h as shown by inhibition of T cell proliferation and induction of apoptosis. Injection of A-MDSCs from Itga1\(^{−/−}\) mice showed equivalent homing into the spleen but a reduced suppressive effect. Interaction studies of A-MDSCs with Teff in the subcapsular red pulp with intravital two-photon microscopy revealed also here that MDSC motility and migration parameters were not altered by VLA-1 deficiency, but the interaction times with Teff were reduced. Together, our data point to a new role of VLA-1 adhesion to collagen IV as a prerequisite for extended contact times with Teff required for suppression.
Visualization of type I immunity using bicistronic IFN-gamma reporter mice in vitro and in vivo
(2006)
IFN-γ is the signature cytokine of Th1 and CD8+ effector cells generated in type I immune responses against pathogens, such as Influenza virus, Sendai virus and the intracellular protozoan parasite Toxoplasma gondii. Understanding the regulation of IFN-γ is critical for the manipulation of immune responses, prevention of immunopathology and for vaccine design. In the present thesis, IFN-γ expression by CD4+ and CD8+ T cells was characterized in detail and the requirement of IFN-γ receptor mediated functions for IFN-γ expression was assessed. Bicistronic IFN-γ-eYFP reporter mice, which allow direct identification and isolation of live IFN-γ expressing cells, were used to visualize IFN-γ expression in vitro and in vivo after infection with the afore mentioned pathogens. Expression of the IFN-γ-eYFP reporter by CD4+ and CD8+ T cells was broadly heterogeneous in vitro and in vivo after infection. Increased expression of the reporter correlated positively with the abundance of IFN-γ transcripts and IFN-γ protein production upon stimulation. eYFP reporter brightness reflected the potential for IFN-γ production, but actual secretion was largely dependent on antigenic stimulation. Increased expression of the reporter also correlated with enhanced secretion of additional proinflammatory cytokines and chemokines and cell surface expression of markers that indicate recent activation. Highly eYFP fluorescent cells were generally more differentiated and their anatomical distribution was restricted to certain tissues. The anatomical restriction depended on the pathogen. IFN-γ expressing CD4+ and CD8+ T cells were generated in IFN-γ receptor deficient reporter mice after infection with Sendai virus or Toxoplasma gondii. However, in the absence of IFN-γ receptor mediated functions, the frequency and brightness of the eYFP reporter expression was altered. Dual BM chimeric mice, reconstituted with wild-type and IFN-γ receptor deficient reporter BM, revealed a T cell-intrinsic requirement for the IFN-γ receptor for optimal IFN-γ expression. Reporter fluorescence intensities were regulated independently of IFN-γ receptor mediated functions. Finally, we propose a model for IFN-γ expression by CD4+ and CD8+ T cells. 2. SUMMARY 10 In summary, the expression of IFN-γ is differentially regulated in CD4+ and CD8+ T cells and after viral or protozoan infections. Additionally, the role of IFN-γ receptor mediated functions for the expression of IFN-γ was determined.
As structural membrane components and signaling effector molecules sphingolipids influence a plethora of host cell functions, and by doing so also the replication of viruses. Investigating the effects of various inhibitors of sphingolipid metabolism in primary human peripheral blood lymphocytes (PBL) and the human B cell line BJAB we found that not only the sphingosine kinase (SphK) inhibitor SKI-II, but also the acid ceramidase inhibitor ceranib-2 efficiently inhibited measles virus (MV) replication. Virus uptake into the target cells was not grossly altered by the two inhibitors, while titers of newly synthesized MV were reduced by approximately 1 log (90%) in PBL and 70–80% in BJAB cells. Lipidomic analyses revealed that in PBL SKI-II led to increased ceramide levels, whereas in BJAB cells ceranib-2 increased ceramides. SKI-II treatment decreased sphingosine-1-phosphate (S1P) levels in PBL and BJAB cells. Furthermore, we found that MV infection of lymphocytes induced a transient (0.5–6 h) increase in S1P, which was prevented by SKI-II. Investigating the effect of the inhibitors on the metabolic (mTORC1) activity we found that ceranib-2 reduced the phosphorylation of p70 S6K in PBL, and that both inhibitors, ceranib-2 and SKI-II, reduced the phosphorylation of p70 S6K in BJAB cells. As mTORC1 activity is required for efficient MV replication, this effect of the inhibitors is one possible antiviral mechanism. In addition, reduced intracellular S1P levels affect a number of signaling pathways and functions including Hsp90 activity, which was reported to be required for MV replication. Accordingly, we found that pharmacological inhibition of Hsp90 with the inhibitor 17-AAG strongly impaired MV replication in primary PBL. Thus, our data suggest that treatment of lymphocytes with both, acid ceramidase and SphK inhibitors, impair MV replication by affecting a number of cellular activities including mTORC1 and Hsp90, which alter the metabolic state of the cells causing a hostile environment for the virus.
Background
During reverse transcription, retroviruses duplicate the long terminal repeats (LTRs). These identical LTRs carry both promoter regions and functional polyadenylation sites. To express full-length transcripts, retroviruses have to suppress polyadenylation in the 5′LTR and activate polyadenylation in the 3′LTR. Foamy viruses have a unique LTR structure with respect to the location of the major splice donor (MSD), which is located upstream of the polyadenylation signal.
Results
Here, we describe the mechanisms of foamy viruses regulating polyadenylation. We show that binding of the U1 small nuclear ribonucleoprotein (U1snRNP) to the MSD suppresses polyadenylation at the 5′LTR. In contrast, polyadenylation at the 3′LTR is achieved by adoption of a different RNA structure at the MSD region, which blocks U1snRNP binding and furthers RNA cleavage and subsequent polyadenylation.
Conclusion
Recently, it was shown that U1snRNP is able to suppress the usage of intronic cryptic polyadenylation sites in the cellular genome. Foamy viruses take advantage of this surveillance mechanism to suppress premature polyadenylation at the 5’end of their RNA. At the 3’end, Foamy viruses use a secondary structure to presumably block access of U1snRNP and thereby activate polyadenylation at the end of the genome. Our data reveal a contribution of U1snRNP to cellular polyadenylation site selection and to the regulation of gene expression.
Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.
In T cells, as in all other cells of the body, sphingolipids form important structural components of membranes. Due to metabolic modifications, sphingolipids additionally play an active part in the signaling of cell surface receptors of T cells like the T cell receptor or the co-stimulatory molecule CD28. Moreover, the sphingolipid composition of their membranes crucially affects the integrity and function of subcellular compartments such as the lysosome. Previously, studying sphingolipid metabolism has been severely hampered by the limited number of analytical methods/model systems available. Besides well-established high resolution mass spectrometry new tools are now available like novel minimally modified sphingolipid subspecies for click chemistry as well as recently generated mouse mutants with deficiencies/overexpression of sphingolipid-modifying enzymes. Making use of these tools we and others discovered that the sphingolipid sphingomyelin is metabolized to ceramide to different degrees in distinct T cell subpopulations of mice and humans. This knowledge has already been translated into novel immunomodulatory approaches in mice and will in the future hopefully also be applicable to humans. In this paper we are, thus, summarizing the most recent findings on the impact of sphingolipid metabolism on T cell activation, differentiation, and effector functions. Moreover, we are discussing the therapeutic concepts arising from these insights and drugs or drug candidates which are already in clinical use or could be developed for clinical use in patients with diseases as distant as major depression and chronic viral infection.